Birchtech Posts 32% Revenue Growth, Launches Nuclear-Grade Water Treatment Line

Event summary

  • Q1 2026 revenue rose 32% YoY to $4.2M, driven by water treatment and air business growth.
  • Launched SEA-IX™ nuclear-grade ion exchange resin line, securing ~$1M in initial orders.
  • Initiated collection efforts on $78M patent infringement judgment; defendants appealed but no bond posted.
  • Uplisted to NYSE American in February 2026, raising $16.4M in concurrent offering.
  • Appointed Michael Mioska as CFO, succeeding Fiona Fitzmaurice.

The big picture

Birchtech's strategic pivot toward water treatment—now contributing to revenue growth—positions it in a high-stakes market for removing contaminants like PFAS. The $78M judgment collection and NYSE uplisting suggest a dual focus on litigation-driven cash flow and institutional investor credibility. Success hinges on converting initial SEA-IX™ orders into recurring utility contracts.

What we're watching

Judgment Collection
Whether Birchtech can successfully collect the $78M judgment amid defendants' appeal and lack of bond posting.
Product Scaling
The pace at which SEA-IX™ can capture share in the $220M addressable market for nuclear and utility water treatment.
Financial Discipline
How the new CFO will balance R&D investment ($0.6M in Q1) with path to profitability.